Encore Medical Device Repair Significantly Expands Its Robotic Instrument Remanufacturing Program

Remanufactured Da Vinci Xi Monopolar Scissors will help hospitals reduce the cost of robotic surgery while reducing the environmental footprint of surgeries

SCOTTSDALE, Ariz., March 25, 2025 /PRNewswire/ — Encore Medical Device Repair (Encore) today announced that it can now offer its customers remanufactured Da Vinci Xi Monopolar Scissors. Encore customers already have access to remanufactured Da Vinci Si Monopolar Scissors as well as a pre-owned robotic instrument program. A recent FDA clearance now expands the company’s robotic instrument portfolio. With this milestone, Encore is offering hospitals and surgery centers a cost-effective and sustainable alternative to purchasing robotic instruments from the original manufacturer.

U.S. hospitals spend more than $2 billion every year on robotic instruments and accessories. Any hospital participating in Encore’s robotic manufacturing program will be able to significantly reduce its costs without compromising quality or patient safety.

“The availability of remanufactured Xi monopolar scissors is a major victory for instrument re-use, a strategy that is absolutely necessary for hospitals in the current economic climate,” says Encore President and COO Tom Milano. “Encore was founded on the idea of instrument stewardship – we need to treat instruments as assets to keep costs down and protect the environment. Restore Robotics and Encore’s collaboration on robotic instrumentation is a great win for resource stewardship.”

It is through Encore’s exclusive collaboration with Restore Robotics that the company is able to offer the Da Vinci Xi remanufactured instruments. Restore Robotics received its 510(k) clearance from the U.S. Food and Drug Administration (FDA) for remanufacturing Da Vinci Xi Monopolar Scissors on March 11, 2025, through its subsidiary Iconocare Health.

“Restore Robotics is deeply committed to helping hospitals reduce the cost of using a surgical robot,” says Restore Robotics CEO Clif Parker. “Our recent clearance is a break-through for robotic instrument re-use as the instrument cleared for remanufacturing is among the most used robotic instruments in U.S. hospitals.”

The remanufactured Xi monopolar scissors are available immediately from Encore Medical Device Repair.

About Encore Medical Device Repair
Encore Medical Device Repair was founded in 2022 on the vision that device and instrument reuse should play a key role in responsible healthcare. To achieve this, the founders knew they had to raise the level of quality, sophistication, transparency, and service in the industry. A focus on the highest-price, highest-utilization instrument categories allows Encore to employ the most qualified technicians and deliver unparalleled service while containing costs.

About Restore Robotics
Based in Panama City Beach, FL, with a state-of-the-art remanufacturing facility in Henderson, NV, Restore Robotics is a pioneer in the surgical robotics field, offering innovative solutions that enhance the performance and sustainability of surgical systems.

Disclaimer: Da Vinci, Da Vinci Xi, and Da Vinci Si are registered trademarks of Intuitive Surgical. Restore Robotics is an independent entity and is not affiliated with Intuitive Surgical®, Inc. or its affiliates. All registered trademarks and product names mentioned herein are the property of their respective owners.

Media Contact: Lori Luechtefeld, lluechtefeld@witstrategy.com, (1310) 210-4757

View original content:https://www.prnewswire.com/news-releases/encore-medical-device-repair-significantly-expands-its-robotic-instrument-remanufacturing-program-302408362.html

SOURCE Encore Medical Device Repair

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

2 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

5 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

5 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

5 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

5 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

5 hours ago